<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="157">
  <stage>Registered</stage>
  <submitdate>1/11/1999</submitdate>
  <approvaldate>1/11/1999</approvaldate>
  <nctid>NCT00002825</nctid>
  <trial_identification>
    <studytitle>Docetaxel in Treating Children With Recurrent Solid Tumors</studytitle>
    <scientifictitle>A PHASE II STUDY OF DOCETAXEL (TAXOTERE) (NSC# 628503) IN CHILDREN WITH RECURRENT SOLID TUMORS</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CCG-0962</secondaryid>
    <secondaryid>NCI-2012-02247</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Brain and Central Nervous System Tumors</healthcondition>
    <healthcondition>Neuroblastoma</healthcondition>
    <healthcondition>Sarcoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Sarcoma (also see 'Bone') - soft tissue</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bone</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Neuroendocrine tumour (NET)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Other</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Brain</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Brain</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - filgrastim
Treatment: drugs - docetaxel

Experimental: Arm I - All patients receive docetaxel with G-CSF every 21 days for up to 12 courses.


Other interventions: filgrastim


Treatment: drugs: docetaxel


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically verified (at original diagnosis) solid tumor that is relapsed or
             refractory The following histologies are eligible:

          -  Sarcomas: Rhabdomyosarcoma Ewing's sarcoma, Peripheral neuroectodermal tumor (PNET),
             Osteosarcoma, Other soft tissue sarcomas

          -  Brain tumors: Ependymoma Primitive neuroectodermal tumor (PNET), High grade
             astrocytoma, Brain stem glioma (histologic verification not required), Neuroblastoma

          -  Measurable disease that can be followed clinically or radiologically required

          -  The following not considered measurable: Bone lesions measured by bone scan or bone
             marrow involvement

          -  Central nervous system disease documented by cerebrospinal fluid cytology

          -  Pleural effusion

        PATIENT CHARACTERISTICS:

          -  Age: 21 and under at original diagnosis

          -  Performance status: 0-3

          -  Life expectancy: Greater than 2 months

          -  In the absence of marrow involvement:

          -  Absolute neutrophil count at least 1,000/mm3

          -  Platelet count at least 100,000/mm3 (transfusion independent)

          -  Hemoglobin at least 9.0 g/dL (transfusion allowed)

          -  With bone marrow involvement:

          -  Absolute neutrophil count at least 750/mm3

          -  Red cell and platelet support possible

          -  Bilirubin normal

          -  ALT/AST less than 1.5 times normal

          -  Alkaline phosphatase less than 2.5 times normal

          -  Creatinine no greater than 1.5 times normal OR creatinine clearance or radioisotope
             glomerular filtration rate at least 60 mL/min

          -  Not pregnant or nursing

          -  Adequate contraception required of fertile women

        PRIOR CONCURRENT THERAPY:

          -  Prior bone marrow transplantation allowed:

          -  Must have stable engraftment without need for significant blood product support or
             cytokine therapy

          -  No concurrent immunomodulating agents

          -  No prior paclitaxel or docetaxel At least 2 weeks since chemotherapy (4 weeks since
             nitrosoureas)

          -  No other concurrent cancer chemotherapy

          -  Concurrent corticosteroids allowed for intracranial pressure in brain tumor patients
             provided patient has been stable for at least 4 weeks

          -  Corticosteroids allowed as pretreatment for docetaxel

          -  At least 2 months since extensive radiotherapy, defined as:

          -  Craniospinal Volume greater than 50% of abdominopelvic cavity

          -  Volume greater than one third of lung volume

          -  No concurrent radiotherapy

          -  No more than 2 prior therapies and fully recovered</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>21</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/1997</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>20</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Princess Margaret Hospital for Children - Perth</hospital>
    <postcode>6001 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>National Cancer Institute (NCI)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Phase II trial to study the effectiveness of docetaxel in treating children with recurrent
      solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing
      so they stop growing or die.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00002825</trialwebsite>
    <publication>Blaney SM, Seibel NL, O'Brien M, Reaman GH, Berg SL, Adamson PC, Poplack DG, Krailo MD, Mosher R, Balis FM. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol. 1997 Apr;15(4):1538-43.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Theodore Zwerdling, MD</name>
      <address>University of California, Davis</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>